Yamanouchi

Yamanouchi
visit the site
For Yamanouchi and Merck KGaA, both of which have a strong commitment in cardiovascular research, these two projects are the result of an alliance to create new drugs in the highly competitive cardiovascular field. Through the alliance, which includes research starting at the early stage of identifying compounds that are promising candidates for clinical development, the companies are sharing in selected areas and specific indication groups their drug discovery technologies, research ideas, and other R&D resources and to jointly evaluate and research their respective seed compounds. Thus, in this partnership, two competitors are synergistically combining their technologies and R&D resources in a global effort to capitalize on the results of their research and make effective use of time and research funds while sharing the risks associated with their endeavors. Pharmaceuticals developed under the alliance will be jointly manufactured and marketed on a global scale. As an R&D-oriented, multinational pharmaceutical company, Yamanouchi is working aggressively on the worldwide development of the drugs it has discovered, making full use of such drug discovery research facilities as its Tsukuba Research Center in Japan and Yamanouchi Research Institute (U.K.) as well as the clinical research facilities of its European subsidiary Yamanouchi Europe B.V. Yamanouchi is actively working to build effective R&D partnerships-such as its alliance with Merck KGaA, which begins with basic research, and its comprehensive joint development alliance in the Japanese market with G.D. Searle Co., of the United States-with leading, global, R&D-oriented pharmaceutical companies with outstanding drug capabilities.

Drug delivery system

14
0
12/8/2013

Rate this site

Related Sites

Yamanouchi Pharma America , Inc.

Note

Not found any data